Pediatric Vaccines Market valued at over USD 48 billion in 2023, the global pediatric vaccines market is witnessing substantial growth driven by increasing immunization rates and n
If you purchase this report now and we update it in next 100 days, get it free!
The pediatric vaccines market has seen significant evolution since the early 20th century, reflecting advancements in medical science and changes in public health policies. Vaccines for children have a storied history, beginning with the development of the smallpox vaccine by Edward Jenner in 1796. This was followed by other pivotal vaccines, such as those for diphtheria, pertussis, and tetanus, introduced in the early 20th century. The mid-20th century marked a breakthrough era with the development of vaccines for polio, measles, mumps, and rubella, which dramatically reduced the incidence of these diseases worldwide. In recent decades, the pediatric vaccines market has expanded significantly due to the introduction of new vaccines and the enhancement of existing ones. The expansion is driven by continuous research and development, aiming to address emerging health threats and improve vaccine efficacy and safety. For instance, the development of vaccines for diseases like pneumococcal disease, rotavirus, and human papillomavirus (HPV) reflects the ongoing efforts to protect children from a broader range of infections. The pediatric vaccines market is heavily influenced by regulatory frameworks and public health policies. Organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) play crucial roles in setting vaccination guidelines and policies. National regulations vary, but most countries have stringent requirements for vaccine approval and monitoring to ensure safety and effectiveness. The introduction of policies such as mandatory vaccination schedules and vaccination programs funded by governments or international agencies, like GAVI (the Global Alliance for Vaccines and Immunization), has been pivotal in increasing vaccine coverage and accessibility in both developed and developing regions.
According to the research report "Global Pediatric Vaccines Market Overview, 2029," published by Bonafide Research, the Global pediatric vaccines market was valued at more than USD 48 Billion in 2023. The pediatric vaccines market has witnessed substantial growth, driven by advances in biotechnology, increased awareness, and supportive public health policies. This market is characterized by the presence of several key players who dominate the sector with innovative products and strategic collaborations. Major pharmaceutical companies such as Pfizer, GlaxoSmithKline (GSK), Merck & Co., Sanofi Pasteur, and AbbVie are prominent in the development and distribution of pediatric vaccines. These companies invest heavily in research and development to create new vaccines and enhance existing ones, addressing emerging health threats and expanding the range of preventable diseases. Technological advancements have also played a crucial role in market growth. Innovations in vaccine technology, such as mRNA vaccines, are opening new avenues for more effective and rapid responses to infectious diseases. The success of mRNA COVID-19 vaccines has heightened interest in this technology and its potential applications for pediatric vaccines. Furthermore, the ongoing development of vaccines targeting diseases like respiratory syncytial virus (RSV) and Group B Streptococcus (GBS) highlights the dynamic nature of the market and the continuous quest to address unmet medical needs. Public health campaigns and education are vital in overcoming hesitancy, while advancements in cold chain logistics are crucial for maintaining vaccine efficacy in diverse geographical regions.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Market Drivers Global Health Initiatives: The expansion of global health initiatives and immunization programs significantly drives the pediatric vaccines market. Organizations such as the World Health Organization (WHO), UNICEF, and GAVI work to increase vaccine coverage worldwide, especially in underserved and low-income regions. These programs aim to reduce the incidence of vaccine-preventable diseases through widespread vaccination campaigns and education. Innovative Vaccine Formulations: Advances in biotechnology and vaccine development have led to the creation of more effective and safer pediatric vaccines. Innovations include combination vaccines that protect against multiple diseases with a single dose, and vaccines with improved safety profiles and longer-lasting immunity.
Market Challenges Public Perception: Vaccine hesitancy, driven by misinformation and fears about vaccine safety, poses a significant challenge to achieving high vaccination coverage. Concerns about potential side effects, coupled with misinformation spread through social media and other channels, can lead to reluctance or refusal to vaccinate children. High Cost of Vaccines: The cost of pediatric vaccines, including both development and purchase, can be high. This is particularly challenging for low-income families and regions with limited healthcare resources. The high cost can lead to disparities in vaccine access and coverage. Ensuring that vaccines are available and properly administered across diverse geographical regions, especially in remote or underserved areas, involves overcoming logistical hurdles such as distribution, storage, and cold chain management.
Market Trends Single-Dose Protection: There is a growing trend towards developing combination and multi-valent vaccines that protect against multiple diseases with a single dose. This approach simplifies vaccination schedules, reduces the number of visits required, and improves adherence. Examples include the MMR vaccine and the pentavalent vaccine that protects against five diseases.
Make this report your own
Have queries/questions regarding a report
Take advantage of intelligence tailored to your business objective
Manmayi Raval
Research Consultant
based on the report, the types are segmented into Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines.
Monovalent Conjugate Vaccines target a single pathogen or disease, using a conjugate vaccine technology that combines a polysaccharide antigen with a protein carrier. This approach enhances the immune response, particularly in young children whose immune systems may not respond robustly to polysaccharide antigens alone. Examples include the Haemophilus influenzae type b (Hib) vaccine and certain formulations of the pneumococcal vaccine. These vaccines are effective in preventing specific diseases and are often used in targeted immunization programs. Multivalent Conjugate Vaccines, on the other hand, are designed to protect against multiple strains or types of a pathogen within a single vaccine. By incorporating multiple antigens into one formulation, these vaccines offer broader protection and simplify vaccination schedules. For instance, the 13-valent pneumococcal conjugate vaccine (PCV13) covers 13 different serotypes of the Streptococcus pneumoniae bacterium, providing comprehensive protection against various strains. Similarly, combination vaccines like the DTaP-IPV-Hib (Diphtheria, Tetanus, Pertussis, Inactivated Poliovirus, and Haemophilus influenzae type b) vaccine streamline the vaccination process by addressing multiple diseases with a single injection.
based on the report, the Disease type is segmented into Varicella, Human Papilloma Virus, Measles, Mumps and Rubella, Pneumococcal Disease and others.
Varicella Vaccines protect against chickenpox, a highly contagious disease caused by the varicella-zoster virus. The varicella vaccine often administered as part of a combination vaccine or as a single antigen vaccine, has significantly reduced the incidence of chickenpox and its complications. It is typically recommended for children between 12-15 months and again at 4-6 years of age. Human Papillomavirus (HPV) Vaccines are designed to prevent infections by human papillomavirus, which can lead to cervical cancer, other genital cancers, and oropharyngeal cancers. The HPV vaccine is recommended for preteens (both girls and boys) around ages 11-12, with catch-up vaccinations available for older individuals. The vaccine has been instrumental in reducing HPV-related cancer rates and genital warts. Measles, Mumps, and Rubella (MMR) Vaccine is a combination vaccine that protects against measles, mumps, and rubella. These diseases, caused by different viruses, were once common and caused significant morbidity. The introduction of the MMR vaccine has dramatically decreased the incidence of these diseases. The vaccine is generally administered in two doses, with the first dose given between 12-15 months and the second dose between 4-6 years. Pneumococcal Disease Vaccine protect against diseases caused by the bacterium Streptococcus pneumoniae, including pneumonia, meningitis, and sepsis. The vaccines, such as the pneumococcal conjugate vaccines (PCV13 and PCV15), are recommended for all children under 5 years of age, with boosters sometimes recommended for older children and adults in certain high-risk groups. Other Vaccine category includes vaccines for a range of other diseases such as rotavirus (which causes severe diarrhea), hepatitis A and B, and pertussis (whooping cough). These vaccines are essential in comprehensive pediatric immunization schedules, addressing both common and less prevalent infectious diseases.
North America leads the pediatric vaccines industry due to its advanced healthcare infrastructure, significant investments in research and development, and robust regulatory frameworks.
Don’t pay for what you don’t need. Save 30%
Customise your report by selecting specific countries or regions
North America's dominance in the pediatric vaccines industry can be attributed to a combination of factors that collectively foster a highly effective and innovative environment for vaccine development and distribution. At the heart of this leadership is the region's advanced healthcare infrastructure, which includes a well-established network of healthcare providers, state-of-the-art medical facilities, and comprehensive vaccination programs. This infrastructure ensures that vaccines are not only developed and manufactured with the highest standards but also effectively delivered to the target populations, including children. Significant investments in research and development (R&D) are another crucial factor driving North America's leadership. Both private sector companies and public institutions in the region, including major pharmaceutical firms and research universities, allocate substantial resources to vaccine innovation. The presence of industry giants such as Pfizer, GlaxoSmithKline (GSK), and Merck & Co., along with a thriving biotech sector, ensures that cutting-edge technologies are rapidly translated into new vaccines. For instance, the rapid development and deployment of mRNA vaccines, highlighted by Pfizer's COVID-19 vaccine, underscore the region's capacity for swift and effective innovation in response to emerging health threats. North America's regulatory frameworks also play a pivotal role in maintaining the region's leadership in the pediatric vaccines industry. Agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada have stringent regulatory processes that ensure the safety, efficacy, and quality of vaccines before they are approved for public use.
Considered in this report
• Historic year: 2018
• Base year: 2023
• Estimated year: 2024
• Forecast year: 2029
Aspects covered in this report
• Pediatric Vaccines Market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation
By Types:
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines
By Disease:
• Varicella
• Human Papilloma Virus
• Measles
• Mumps and Rubella
• Pneumococcal Disease
• Others
The approach of the report:
This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.
Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Pediatric Vaccines industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.
Request Table of Contents
Why Bonafide Research?
Our seasoned industry experts bring diverse sector experience, tailoring methodologies to your unique challenges.
Leveraging advanced technology and time-tested methods ensures accurate and forward-thinking insights.
Operating globally with a local touch, our research spans borders for a comprehensive view of international markets.
Timely and actionable insights empower swift, informed decision-making in dynamic market landscapes.
We foster strong client relationships based on trust, transparency, and collaboration.
Our dedicated team adapts and evolves strategies to meet your evolving needs.
Upholding the highest standards of ethics and data security, we ensure confidentiality and integrity throughout the research process.
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. Read More
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. Read More
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. Read More
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). Read More